Navigation Links
Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial

e dose escalation trial in patients with advanced hematologic malignancies. Patients are dosed for 21 days on a 28-day cycle. A minimum of three patients are treated at each dose level. The study is divided into two arms, one for treatment of leukemia patients and the other for treatment of patients with lymphoma and myeloma. For the leukemia arm of the study, patients are currently being treated at the tenth dose level, 250 mg twice daily. For the lymphoma and myeloma arm, patients are currently being treated at the sixth dose level, 150 mg twice daily.

Positive Safety and Tolerability Data: The goal of the Phase I study is to establish the safety, tolerability and pharmacokinetics of the drug. Thus far, 104 one-month cycles of AVN944 have been initiated in 46 patients and the compound is well tolerated. Pharmacokinetics measurements indicate dose proportional plasma levels of AVN944 during treatment and sustained plasma concentrations at the dose levels tested thus far.

Early Activity Indicators: This Phase I study is designed to evaluate several pharmacodynamic and efficacy-related endpoints. Upon entering the trial, all patients have refractory, progressive disease and have failed all prior therapies. Thus far, 18 of 39 evaluable patients (46%) showed stabilized disease after one cycle of treatment with AVN944. These include patients with both leukemia and multiple myeloma. Patients who have achieved stable disease following completion of a one-month treatment cycle with AVN944, as determined by the clinical investigator, may be advanced to a subsequent cycle.

In the multiple myeloma cohort 60% of the patients have achieved stabilized disease after one month. Two of these patients completed five months of treatment and two others completed one full year of treatment. One AML patient has completed 8 monthly cycles of treatment.

Positive Dose Dependent Biomarker Data: The AvalonRx(R) platform has identified selected biomarkers from pati
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
2. Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2007 Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
(Date:10/30/2014)... WOONSOCKET, R.I. , Oct. 30, 2014 CVS ... entered into new clinical affiliations with three leading regional health ... for patients. The collaborating health systems include Baptist Health System ... affiliated hospitals which include Commonwealth Health in Pennsylvania ... Arizona , and Tennova Healthcare in ...
(Date:10/30/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or ... in China , today announced that ... results on Wednesday, November 5, 2014 after the market ... a conference call at 7:30 a.m. Eastern Time on ... Time on November 6, 2014, to discuss third quarter ...
Breaking Medicine Technology:Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4China Biologic to Report Third Quarter 2014 Financial Results 2
... of a new cytokine called IL-35 could allow clinicians ... response, MEMPHIS, Tenn., Nov. 21 Investigators at ... molecule,that prevents immune responses from running amok and damaging ... new treatments for cancer, using,vaccines; for autoimmune diseases, such ...
... Nov. 20 A new study,released by Indiana ... in immediate and significant improvements in heart,health, particularly ... decrease in,hospital admissions for heart attacks, also known ... prior cardiac history in Monroe,County, Indiana versus the ...
Cached Medicine Technology:St. Jude Finds Molecule That Could Improve Cancer Vaccine and Therapy for Other Diseases 2Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows 2
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, ... additional $100 million in the fight against the Ebola outbreak ... the World Bank,s total pledge to more than $500 million, ... to the three hardest-hit countries -- Guinea, Liberia and Sierra ... has increased significantly in recent weeks, but we still have ...
(Date:10/31/2014)... Oct. 30, 2014 (HealthDay News) -- Wearing masks made ... festivities that could be risky for children with asthma, ... association advises parents to be proactive about managing their ... enjoyable. Some of the steps they recommend parents ... and haunted houses are exciting adventures that can lead ...
(Date:10/31/2014)... Steven Reinberg HealthDay ... Leprosy, although quite rare, continues to appear in the United ... new cases are reported in the United States each year, ... said. That compares to about 250,000 cases that occurred worldwide ... times, leprosy is an infectious disease that causes skin sores, ...
(Date:10/31/2014)... — A new report by Milken Institute School ... George Washington University examines the challenge of maintaining ... enrolled in Covered California and who are also ... Services Program (CPSP). The CPSP, whose roots are ... ever developed for low-income pregnant women, makes enriched ...
(Date:10/30/2014)... an institutional patient registry on stereotactic body radiotherapy ... of tumors, for medically inoperable, early stage lung ... 2012, according to research presented today at the ... Symposium is sponsored by the American Society of ... Oncology (ASTRO), the International Association for the Study ...
Breaking Medicine News(10 mins):Health News:World Bank Pledges $100M More to Fight West Africa's Ebola Outbreak 2Health News: Halloween Safety Tips for Kids With Asthma 2Health News:Leprosy Still Occurs in U.S., CDC Reports 2Health News:Leprosy Still Occurs in U.S., CDC Reports 3Health News:Report examines health care challenges for pregnant women enrolled in covered California 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3
... cancer of the eye need not have to remove their ... The results of the Collaborative ocular Melanoma ... found that survival rates were the same regardless of whether ... radiation therapy.// , Davidorf, Professor ...
... affects women in their 30s and 40s, especially women.The illness ... cause pain, inflammation and joint destruction. , ... condition, but one third of the patients discontinue treatment early ... taking Methotrexate are prone for their drug-related liver damage .This ...
... exercise can improve their health or it would not make a ... Consensus statements published by the American College of ... researchers often can't tell how much health-improvement pay-off will result from ... make a difference at all. , , ...
... levels is becoming an increasingly important part of a medical ... or 'good' cholesterol) levels should be high, and low density ... At Johns Hopkins ... to measure non-HDL cholesterol too. This is the difference between ...
... to kill the deadly Hepatitis E virus has been designed by ... would kill the virus by cutting RNA. , , ... animals. The cloned virus could also be used for diagnostic purposes ... For this, the team had produced ...
... in tomato products, such as tomato sauce and ketchup, have ... especially prostate cancer, but the reason for such an action ... that lycopene, which is found in tomato products and other ... and treating the disease in its earliest stages.// ...
Cached Medicine News:Health News:How much can exercise improve health? 2Health News:Protective effects of tomatoes in prostate cancer 2
Microwell IRMA for the detection of Intact PTH...
Mircrowell EIA for detection of Intact PTH...
... Loading Units with Stainless Steel Staples for ... ,Utilizing a disposable loading unit, the LDS-2™ ... ligate the tissue within the cartridge jaw ... between the two closed clips. The instrument ...
... The Auto Suture™ Powered LDS™ single ... ligate tissue within the cartridge jaw and ... the two closed staples. , ,The ... with titanium staples have application in abdominal, ...
Medicine Products: